Chronic headaches are headaches that occur on 15 or more days per month for at least three months. That threshold separates them from episodic headaches, which most people experience occasionally and which resolve without ongoing management. Chronic headaches are not a single disease but an umbrella category covering several distinct disorders, each with its own pattern of pain, underlying biology, and treatment approach. Understanding which type you are dealing with matters, because a strategy that works well for one can be ineffective or even counterproductive for another.
The Major Types of Chronic Headache
The most common chronic headache disorders fall into a few recognizable categories. They share the “15 or more days per month” criterion but differ in nearly everything else: where the pain sits, how long attacks last, what other symptoms come with them, and what drives them biologically.
Chronic Migraine
Chronic migraine means having headache on 15 or more days per month, with at least eight of those days meeting criteria for migraine. That typically means moderate-to-severe throbbing pain, often one-sided, accompanied by nausea, sensitivity to light and sound, or both. Many people with chronic migraine started with occasional migraines that gradually became more frequent over months or years. The mechanism behind that progression involves a neuropeptide called CGRP, which is released from nerve endings in the trigeminal system and triggers a cascade of inflammation and nerve sensitization around the brain’s blood vessels and covering membranes.
When CGRP is released repeatedly, it does not just cause pain in the moment. It sensitizes the nerve pathways that carry pain signals, making them fire more easily each subsequent time. Research shows that CGRP released inside a cluster of nerve cells called the trigeminal ganglion interacts with surrounding cells to keep those nerves in a heightened state. Over time, this peripheral sensitization can drive changes in the brain itself, a process called central sensitization, where the neurons receiving pain signals become persistently hyperexcitable even between attacks.
1PubMed Central. CGRP and the Trigeminal System in Migraine That shift from activity-dependent to activity-independent sensitization may be a key mechanism driving the transition from episodic to chronic migraine.
Animal studies reinforce this picture. Repeated stimulation of pain-sensing nerve fibers on the brain’s outer covering leads to progressively worsening skin sensitivity and neuronal hyperexcitability, along with impairment of the brain’s built-in pain-dampening systems.
2PubMed. General trigeminospinal central sensitization and impaired descending pain inhibitory controls contribute to migraine progressionChronic Tension-Type Headache
Chronic tension-type headache produces a pressing or tightening sensation, usually on both sides of the head, that can persist for hours or be nearly continuous. Unlike migraine, it rarely comes with nausea, vomiting, or strong sensitivity to light. The pain is generally mild to moderate but relentless, which makes it debilitating in its own way.
For a long time, tension-type headache was blamed on tight muscles in the scalp and neck. The reality is more complex. While many people with chronic tension-type headache do have increased tenderness when the muscles around their skull are pressed, a substantial number do not, which means local muscle tension alone cannot explain the pain.
3PubMed Central. Pericranial tenderness in chronic tension-type headache: the Akershus population-based study of chronic headache Research points to central sensitization as a major factor here too. Pain thresholds measured not just on the head but also on the fingers are significantly lower in people with chronic tension-type headache compared to healthy controls, suggesting the entire pain-processing system has become more reactive.
4PubMed. Central sensitization in tension-type headache–possible pathophysiological mechanismsBrain mapping studies have added another layer. When researchers induced muscle pain in people with chronic tension-type headache and in healthy controls, the controls’ brains showed a dampening response that reduced the pain signal over time. In the chronic headache group, that dampening was absent, meaning their brains could not properly inhibit incoming pain signals from muscles.
5Brain. Abnormal pain processing in chronic tension-type headache: a high-density EEG brain mapping studyCluster Headache
Cluster headache is less common but far more intense. Attacks bring severe, stabbing pain around one eye, lasting anywhere from 15 minutes to three hours, and they tend to arrive in clusters: daily or near-daily episodes for weeks or months (a “bout”), followed by a remission period. When bouts last longer than a year without remission, or remission periods are shorter than three months, the condition is classified as chronic cluster headache.
What sets cluster headache apart is its clockwork timing. Attacks often strike at the same hour each day, frequently waking people from sleep. Imaging studies have identified the posterior hypothalamus, a brain region that regulates circadian rhythms, as a key player. During an attack, this area lights up on brain scans, and structural imaging shows it is subtly enlarged in cluster headache patients compared to controls.
6PubMed. Hypothalamic involvement and activation in cluster headache The hypothalamus appears to initiate and maintain the attacks, while the pain and the accompanying symptoms on the affected side of the face, such as tearing, nasal congestion, or a drooping eyelid, are generated through the trigeminal-autonomic reflex.
7PubMed Central. Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and DiagnosisNew Daily Persistent Headache
New daily persistent headache, or NDPH, is one of the more frustrating chronic headache diagnoses. It begins abruptly, often on a specific date that the person can remember clearly, and then simply does not go away. The pain itself is not distinctive: it can feel like a tension-type headache, or it can have migraine-like features such as throbbing and light sensitivity.
8PubMed Central. New daily persistent headache: a systematic review on an enigmatic disorderThe cause remains poorly understood. One lead involves inflammation within the central nervous system. A study found elevated levels of a pro-inflammatory protein called TNF-alpha in the spinal fluid of nearly all NDPH patients tested, while their blood levels of the same protein were normal, suggesting the inflammation is localized to the brain and spinal cord.
9PubMed. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine NDPH sometimes follows a viral illness or stressful life event, which fits with the idea that an initial immune trigger may set the process in motion. Treatment is difficult. Antiviral drugs and medications that target neuroinflammation may help when an infection or severe inflammation is suspected, but many cases remain stubbornly resistant to standard headache therapies.
10PubMed. New Daily Persistent Headache (NDPH): Unraveling the Complexities of Diagnosis, Pathophysiology, and TreatmentWhat Drives Headaches to Become Chronic
Not everyone who gets headaches develops a chronic pattern. Several factors push the process along, and understanding them is useful because some are modifiable.
Overuse of acute pain medication is one of the most well-documented accelerants. When someone takes painkillers, triptans, or combination analgesics frequently, often defined as 10 to 15 or more days per month depending on the drug class, the brain’s pain-regulating systems can paradoxically become more permissive of pain. Evidence suggests that the mechanisms behind medication overuse headache overlap substantially with those behind migraine itself, including increased cortical spreading depression and shifts in the brain’s balance between pain facilitation and pain inhibition.
11PubMed Central. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies The clinical implication is straightforward: if you find yourself reaching for acute medications on more than about two days a week, that pattern itself can be making your headaches worse.
Sleep disturbances are another independent risk factor for progression from episodic to chronic headache. Snoring, fragmented sleep, and poor sleep quality all appear to raise the risk.
12PubMed. Sleep-related headaches Hormonal fluctuations play a role as well, particularly for women with migraine. Drops in estrogen levels, especially after an extended period of higher estrogen, are a well-established migraine trigger. Women with a history of migraine appear to be more sensitive to these physiological swings in estrogen than women without migraine.
13PubMed Central. The complex relationship between estrogen and migraines: a scoping review Research supports that reducing the magnitude of estrogen decline can help prevent menstrually related attacks.
14PubMed Central. Migraine and estrogenPsychiatric comorbidities, especially depression and anxiety, have a bidirectional relationship with migraine. Each condition raises the risk of the other, and they amplify each other’s severity across all age groups, including children and adolescents.
15PubMed. Unraveling the connections between migraine and psychiatric comorbidities: A narrative review This does not mean chronic headaches are “just stress” or “all in your head.” It means the neural pathways involved in mood regulation and pain processing overlap, and treating one without addressing the other often gives incomplete results.
The Gut-Brain Connection
A more recently explored contributor is the gut microbiome. The gut communicates with the brain through a network of immune signals, nerve pathways, and chemical messengers, and disruptions in that communication appear to influence headache severity and frequency. Studies comparing the gut bacteria of people with migraine to those of headache-free controls have found meaningful differences, both in which species are present and in how those microbial communities function.
16PubMed. The Gut Microbiome and Migraine: Updates in Understanding Genetic analysis methods designed to test for cause-and-effect relationships have supported the idea that gut microbiome composition is not merely correlated with migraine but may actually contribute to it. Inflammatory mediators, serotonin pathways, and stress hormones all appear to be involved in this gut-brain interaction.
17PubMed Central. A review on gut microbiota and migraine severity: a complex relationshipThis line of research is still maturing, and no one is yet prescribing specific probiotics as a headache treatment with strong clinical backing. But it does suggest that gut health, diet, and the overall state of the immune system may be part of the picture for some people, and it opens the door to treatment approaches that wouldn’t have been considered a decade ago.
Treatments That Target the Underlying Biology
Treatment for chronic headaches has changed substantially in recent years, especially for chronic migraine. Older preventive medications, such as certain blood pressure drugs, antidepressants, and anticonvulsants, are still used and can be effective, but they were originally designed for other conditions and repurposed for headache. The newer wave of treatments was built from the ground up around headache biology.
CGRP-Targeting Medications
Because CGRP is so central to migraine pathophysiology, blocking it has become a major treatment strategy.
18PubMed Central. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting Two classes of drugs do this. Monoclonal antibodies (injectable medications given monthly or quarterly) bind to either CGRP itself or its receptor and keep it from activating pain pathways. Gepants are small-molecule pills that block the CGRP receptor and can be used both to treat attacks acutely and to prevent them.
19PubMed Central. Gepants for Acute and Preventive Migraine Treatment: A Narrative ReviewA systematic review and network meta-analysis of phase 3 trials found that all of these CGRP-targeting medications reduced monthly migraine and headache days compared to placebo, and that patients were significantly more likely to achieve at least a 50 percent reduction in attacks.
20PubMed. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials These are not miracle drugs; not everyone responds, and insurance access can be a barrier. But for people who have failed older preventives, they represent a genuinely different approach.
Botulinum Toxin Injections
OnabotulinumtoxinA, commonly known by the brand name Botox, is approved specifically for chronic migraine and is given as a series of injections around the head and neck roughly every 12 weeks. Its mechanism goes beyond simply relaxing muscles. Once injected, the toxin gets taken up by sensory nerve terminals and blocks the release of pain-related molecules including CGRP itself, substance P, and glutamate. It also prevents the insertion of certain pain-sensitive receptors into nerve cell membranes, which reduces how easily those nerves can fire.
21PubMed Central. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review The net effect is a dampening of both the peripheral and central sensitization that maintain the chronic migraine cycle.
Neuromodulation Devices
Several devices that use electrical or magnetic stimulation to modulate nerve activity have been cleared for headache treatment. Non-invasive vagus nerve stimulation, which delivers mild electrical pulses to the vagus nerve through the skin, has been studied for both migraine and cluster headache. For chronic cluster headache, a randomized controlled trial found that adding vagus nerve stimulation to standard treatment reduced attacks by about four more per week compared to standard care alone, and the proportion of patients achieving at least a 50 percent reduction in attacks was roughly five times higher.
22PubMed Central. Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled studyFor migraine, the results depend on the type of vagus nerve stimulation used. Meta-analysis found that one form delivered through the ear significantly reduced migraine days and headache intensity, while another form applied to the neck improved the proportion of responders but did not significantly reduce monthly migraine days.
23PubMed Central. Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis of randomized controlled trials These devices are generally well-tolerated and may be especially appealing for people who cannot take or prefer not to take daily medications.
Behavioral Approaches and Why They Matter
Medication alone rarely solves chronic headaches completely. Cognitive behavioral therapy, or CBT, has a solid evidence base as an add-on treatment. A meta-analysis of CBT trials for migraine found significant reductions in migraine-related disability scores compared to control groups.
24PubMed Central. Cognitive Behavioral Therapy for Migraine Headache: A Systematic Review and Meta-Analysis CBT for headache is not about convincing you the pain is imaginary. It focuses on identifying and changing thought patterns and behaviors that amplify pain, improving stress management, and restoring functional activities that headache has crowded out of daily life.
When CBT is combined with biofeedback, a technique where you learn to control physiological responses like muscle tension, the results appear to be even better. Research comparing CBT alone, biofeedback alone, and the combination found that all three groups showed significant decreases in pain catastrophizing, sleep quality, and headache-related disability, but the combined approach produced the strongest and most lasting improvements.
25PubMed. Cognitive Behavioral Therapy and Biofeedback for Chronic Headache: Effects on Pain Catastrophizing, Sleep Quality, and DisabilityThe Economic and Functional Toll
Chronic headaches are consistently associated with greater disability and productivity loss, more medical consultations, and higher costs than episodic headaches.
26PubMed. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review The burden is not just personal. A systematic review of economic studies across developed countries found that while the specific dollar figures vary, the overall picture is remarkably consistent: direct medical costs from hospitalizations and medications are the largest component, but lost productivity from missed work and impaired function on the job adds substantially to the total.
27PubMed Central. Economic burden of chronic migraine in OECD countries: a systematic reviewThis economic reality matters beyond the abstract because it affects how aggressively chronic headache gets treated. Many people minimize their condition because their individual attacks feel “just” like a headache, and healthcare systems sometimes mirror that attitude. But when a condition drives over a hundred million bedridden days per year in the United States alone and costs employers billions in lost productivity, it is not a minor inconvenience.
28PubMed. Burden of migraine in the United States: disability and economic costsHeadache in Children and Adolescents
Chronic headache is not an adults-only problem. Headache is one of the most common neurological complaints in children, and the spectrum is broad. The presentation in younger patients can differ from adults in ways that complicate diagnosis: attacks may be shorter, pain may be bilateral rather than one-sided, and accompanying symptoms like abdominal discomfort can be more prominent than the classic migraine features adults describe.
29PubMed Central. Pediatric headache: a narrative review The bidirectional relationship between headache and mood disorders noted earlier applies in this age group too, and anxiety in particular tends to be more common in children with chronic headache than in their peers. For parents, the practical takeaway is that recurrent headaches in a child deserve medical evaluation rather than a wait-and-see approach, especially when they interfere with school or social activities.